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In recent years, the world has seen a surge in extended-spectrum β-lactamase (ESBL)-producing bacteria. 
Among antibiotic resistance mechanisms, the production of β-lactamase is the most rapidly developing and 
clinically significant in Gram-negative bacteria. In the present study, a total of 275 stool samples were 
collected from students of both sexes in three student residencies of Eduardo Mondlane University-
Mozambique from January to February 2016. All samples were cultured on MacConkey agar with 
ceftriaxone (1mg/L) and without ceftriaxone. The isolates were biochemically identified with API20E test. 
Confirmed E. coli and Klebsiella spp. isolates were subjected to antimicrobial susceptibility testing by the 
disc diffusion method and ESBL strains were confirmed with the disc approximation method. From these 
samples, 56 ESBL positive E. coli(n=35) and Klebsiella spp. (n=21) strains were isolated. Among the 
ESBL-positive isolates, 39.3% (22/56) were cefoxitin resistant and none were confirmed as carbapenemase 
producers. The frequency of ESBL colonization in both sex were similar for E. coli and Klebsiella spp. 
Among the ESBL-positive isolates, 50% (28/56) of the isolates only contained class A ESBLs, 5.4% (3/56) 
only class C ESBLs, and 44.6% (25/56) both class A and C ESBLs. Among the E. coli strains, 100% were 
resistance to ampicillin, and both E. coli and Klebsiella spp. demonstrated69.6% resistance to tetracycline 
and cotrimoxazole, 62.5% to ceftazidime, 33.9% to ciprofloxacin, and 34.8% to cefoxitin. None of the 
isolates showed resistance to meropenem. In total, 78.6 % of ESBL strains were defined as multi-resistant. 
The ERIC-PCR demonstrated low similarity among the strains. This study demonstrated that the carriage 
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CHAPTER I. INTRODUCTION AND LITERATURE REVIEW 
1.1.  INTRODUCTION 
In recent years, the world has seen a surge in extended-spectrum β-lactamase (ESBL) producing 
bacteria (1). Among resistance mechanisms, the production of β-lactamase is the most rapidly 
developing and clinically significant in Gram-negatives (2,3). 
 
Members of the Enterobacteriaceae family are inhabitants of the intestinal flora and are among 
the most common human pathogens that cause community and hospital-acquired infections. They 
have the propensity to spread easily between humans through hand carriage, contaminated food 
and water, and to acquire genetic material through horizontal gene transfer often mediated by 
plasmids and transposons (4). 
 
The transmission of ESBL-positive bacteria may also occur via the faecal-oral route and is 
facilitated by overcrowding. Among the risks factors for colonization with ESBL, the literature 
describes prolonged hospital stays, recent surgery, prior antibiotics use, particularly quinolones 
and third-generation cephalosporins, but also cotrimoxazole, aminoglycoside, and metronidazole 
(32,36). 
 
The commensal glut flora is a very highly populated ecosystem and its constituents may, at later 
stages, become a source of extra-intestinal infections. Resistance determinants may also spread to 
other members of the micro-biota, including potential pathogens (5). 
 
Among members of the Enterobacteriaceae family, the production of extended spectrum β-
lactamases (ESBL) is an important mechanism of resistance to β-lactam antibiotics (6).Escherichia 
coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) are common opportunistic pathogenic 
species of Enterobacteriaceae that frequently incorporate ESBL-encoding genes (7).ESBL 
production is often encoded on plasmids (8) that have a high capacity for spread via horizontal 
gene transfer mechanisms (9). 
 
Β-lactamases are a large group of enzymes capable of hydrolyzing the β-lactam ring of various 
groups of β-lactam antibiotics thus rendering them inactive (10,11,12,35). Among the β-
lactamases, extended-spectrum β-lactamases have a broad substrate range including third 
generation cephalosporins, and are by the classical definition inhibited by clavulanic acid (13). 
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Since the early 1980s, third-generation cephalosporins have become an important weapon in the 
treatment of severe bacterial infections, and the acquisition of ESBL enzymes by a high number 
of bacterial species is thus a cause for great concern (14). 
Data on the spread of ESBL-producing bacteria in Sub-Saharan Africa is needed to assess the 
extent of this emerging health threat in resource-poor settings (1), but information about the 
epidemiology of ESBL-producing bacteria in this region of Africa is still limited. There are only 
sporadic reports about the prevalence of ESBL-producing bacteria in clinical isolates, and very 
few studies have systematically collected data on the prevalence of colonization with these 
pathogens (15).). 
Our knowledge about the prevalence of ESBL is even more limited concerning clinical isolates 
from Mozambique and particularly Maputo province. The prevalence of ESBL colonized subjects 
still remains unknown. 
 
No study has been done to determine the rate of faecal colonization of antibiotic resistance in E. 
coli and K. pneumoniae/Klebsiella spp. among students at Eduardo Mondlane University, Maputo. 
 
Research Question: What is the prevalence of colonization by ESBL-positive E. coli and K. 








1.2. AIM & OBJECTIVES 
Aim 
 To explore the prevalence of ESBL-positive E. coli and Klebsiella spp. carriage in students 
living in the University residence at Eduardo Mondlane University. 
 
Objectives 
 To isolate and confirm the identity of E. coli and Klebsiella spp. from stool samples of 
University students. 
 To correlate the frequency of E. coli and Klebsiella spp. ESBL colonization with gender, 
use of antibiotics and hospitalization. 
 To ascertain the antibiotic susceptibility of ESBL-positive isolates against an appropriate 
panel of antibiotics by standardized agar disc diffusion and/or minimum inhibitory 
concentration (MIC) determinations using CLSI guidelines. 
 To phenotypically confirm the presence of ESBLs using the double-disc synergy test/E-
test.  
 To identify the ESBL genes by PCR and sequencing. 












1.3.   LITERATURE REVIEW 
1.3.1. Enterobacteriaceae family 
The Enterobacteriaceae family is the most heterogeneous group of Gram-negative bacilli of 
medical importance. The Enterobacteriaceae are the cause of a large group of diseases in humans, 
including 30% to 35% of all bacteremias, more than 70% of urinary tract infections (UTI) and 
many intestinal infections (16). They are transmitted both from other animals or humans and from 
the inanimate environment. Many infections arise from the body’s normal flora when opportunities 
are provided by medical, surgical or other therapies (17). 
E. coli and Klebsiella pneumoniae are members of the Enterobacteriaceae family and commensal 
members of the intestinal glut flora that can cause opportunistic infection (16). 
 
1.3.2. Escherichia coli 
E. coli is a ubiquitous human pathogen (7,18). It is a common cause of urinary tract infections 
(UTI) (7,12) and bacteremia in humans of all ages. It is a frequent cause of varied organ infections, 
ranging from the biliary system to the CNS. The spectrum of pathology can range from a 
spontaneously resolving cystitis to a life-threatening sepsis syndrome. 
There is a variety of reasons for the increased prevalence of antibiotic resistant E. coli. One of 
them is that E. coli is an organism known for its flexible genome and propensity to exchange 
genetic material (7). 
E. coli is the main aerobic component of the mixed flora in intra-abdominal infections (12). E coli 
has concomitantly become the most prevalent species among ESBL-producing 
Enterobacteriaceae isolates in community. Such isolates have been recognized as a common cause 
of hospital and community-onset infections.  
 
1.3.3. Klebsiella pneumoniae 
Klebsiella pneumoniae is an important human pathogen, causing predominantly nosocomial 
infections (19,20). Its most common mechanism of resistance to oxyimino-cephalosporins is the 
production of extended-spectrum β-lactamases (19). 
In humans, K. pneumoniae is present as a saprophyte in the nasopharynx and the gastrointestinal 




Klebsiella pneumoniae is responsible for up to 10% of all nosocomial infections, and this 
proportion has been increasing due to the emergence and progressive spread of multidrug 
resistance and specifically the ESBL strains in hospital settings (21). In some countries the 
prevalence of Klebsiella pneumoniae ESBL-producer approaches 50%(22). 
 
1.3.4. Mechanism of resistance in Enterobacteriaceae 
Antibiotic resistance is now regarded as a major public health problem. In comparison with 
infections caused by susceptible bacteria, those caused by multidrug-resistant bacteria are 
associated with higher mortality, as well as increased costs because of prolonged hospital stay and 
the need for more expensive antibiotics as therapy (23). 
In many developed countries, the use of antibiotics is to some degree controlled. This is generally 
not the case in developing countries, where the treatment of bacterial infections is empirical 
(24,25). Hopefully, interventions to restrict and improve antibiotic use may slow down the problem 
of resistance. 
Enterobacteriaceae may become resistant to all β-lactam antibiotics and frequently co-resistant to 
most other antibiotics, leaving very few treatment options. Since the 1950s and 60s, when broad-
spectrum antibiotics became available for the treatment of Gram-negative infections, 
Enterobacteriaceae have acquired a growing range of mechanisms to evade these agents. In 
particular, β-lactam antibiotics such as penicillins and cephalosporins are vulnerable to hydrolysis 
by enzymes called β-lactamases (26). 
 
1.3.5. β-Lactam Antibiotics 
The β-lactam class of antibiotics constitutes the largest family of antibiotics, widely used in clinical 
practice for the treatment of community-acquired and hospital-acquired infections (27). Theβ-
lactams are classified into penicillins, cephalosporins, carbapenems, monobactams and β-
lactamase inhibitors (28).All β-lactam antibiotics interfere with bacterial cell wall synthesis by 
inhibiting the transpeptidase enzyme forming cross links between peptide chains linked to the 
peptidoglycan framework. Inhibition of this function leads to lysis of the bacterial cell. 
 
1.3.6.  Extended Spetrum β-Lactamase (ESBL) 
ESBLs were initially identified as variants of the common SHV-1 or TEM-1 β-lactamase, often 
differing from the parent enzymes by only one or two amino acids (27). Based on substrate 
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specificities, the β-lactamase family is divided into 4 functional groups: penicillinases, extended-
spectrum β-lactamases (ESBLs), carbapenemases, and AmpC-type cephalosporinases (24). 
Alternatively, β-lactamases can be classified on the basis of structural relationship into Ambler class 
A (serine β-lactamases including classical ESBLs inhibited by clavulanic acid), class B (metallo-β-
lactamases), class C (serine β-lactamases including AmpC enzymes not inhibited by clavulanic acid) 
and class D (OXA β-lactamase). β-lactamase production is the cardinal mechanism of resistance to 
β-lactams in Gram-negative organisms. Some species produce chromosomal β-lactamases, but 
plasmid-mediatedβ-lactamases have become prevalent among many Gram-negative bacteria 
during the past 50 year (29).  
Plasmid mediated production of enzymes inactivate modern expanded-spectrum cephalosporins 
by hydrolyzing their β-lactam ring. This is the most important mechanism of resistance in 
Enterobacteriaceae (24,30). The successful spread of these plasmids is often attributed to selective 
pressure resulting from long use of antibiotics in clinical and veterinary medicine (31). 
More than 200 types of ESBLs, the results of multiple mutations, have been described in various 
species of the Enterobacteriaceae family and other non-enteric organisms, including 
Pseudomonas aeruginosa and Acinetobacter spp. (32).High rates of intestinal ESBL colonization 
have been reported in Asia, with predominance of CTX-M enzymes (33). 
In Europe, there was an increase in invasive infections caused by Klebsiella pneumoniae and 
Escherichia coli resistant to third-generation cephalosporins between 1999 and 2008. The SMART 
study concluded that in Europe, the ESBL prevalence among E. coli and K. pneumoniae was 17.6% 
and 38.9%, respectively. In North America, the prevalence was 8.5% and 8.8%, respectively. In 
Asia, the prevalence of ESBL among E. coli was found to be 5% and among K. pneumoniae 0%, 
in New Zealand this prevalence varies between 67 and 61%, respectively  (34).  
 
Faecal carriage of ESBL in África 
 
In Africa, the prevalence of ESBL has been researched at local levels but not summarized for the 
continent as a whole (34). Some reported studies conduted in our continent have shown high 
prevalence of ESBL. A study conducted in Bangui, Central African Republic, revealed 59% of 
ESBL carriage, one of the highest reported worldwide (37).  Another study of ESBL carriage 
conducted in North Africa (Casablanca, Marrocos), in community setting has found 4.5% of 








1.4. Chapter structure 
This research presents the following chapters: 
Chapter 2. Manuscript:for publication entitled “Faecal Carriage of Extended-Spectrum β-
Lactamase-Producing Escherichia coli and Klebsiella spp. in Mozambican University Students". 
The manuscript addresses the objectives stated above. 
Chapter 3. Conclusion: This chapter describes the conclusions, the limitations of the study, the 
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CHAPTER 2: MANUSCRIPT 
 
The findings are reported in the following manuscript intended for submission to the African 
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In recent years, the world has seen a surge in extended-spectrum β-lactamase (ESBL)-producing 
bacteria (1). Among antibiotic resistance mechanisms, the production of β-lactamase is the most 
rapidly developing and clinically significant in Gram-negative bacteria (2,3). ESBLs have a broad 
substrate range including third and fourth generation cephalosporins and are, by the classical 
definition, inhibited by clavulanic acid (4). ESBL genes are often carried on plasmids(5) that have 
a high capacity for spreading via horizontal gene transfer mechanisms(6,7). 
 
The commensal gut flora is a highly populated ecosystem, the bacterial constituents of which carry 
resistance genes that can spread to other members of the micro-biota (8). These include 
Escherichia coli and Klebsiella pneumoniae, which may, at later stages, become a source of extra-
intestinal infections. Both E. coli and K. pneumoniae are common opportunistic pathogens that 
frequently harbor ESBL-encoding genes (9).  
 
Among the risks factors associated with the colonization with ESBL are prolonged hospital stay, 
recent surgery, and prior antibiotics use, particularly quinolones, third-generation cephalosporins, 
cotrimoxazole, aminoglycoside, and metronidazole (10-11). 
 
Data on the epidemiology of ESBL-producing bacteria in Sub-Saharan Africa is still limited. There 
are only sporadic reports about the prevalence of ESBL-producing bacteria in clinical isolates, and 
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A total of 275 stool samples were collected from students of both sexes in three student residencies 
of Eduardo Mondlane University-Mozambique within a six-week period, from January to 
February 2016. All samples were cultured on MacConkey agar with ceftriaxone 1mg/L and 
without ceftriaxone. From these samples, 56 ESBL positive E. coli and Klebsiella spp. strains were 
isolated. Two strains were isolated from the same student. These putative ESBL-producers 
constituted the study sample. 
 
Identification and susceptibility test 
All the lactose-positive isolates growing on MacConkey agar impregnated with 1mg/L ceftriaxone 
were subjected to identification tests using API20E. Confirmed E. coli and Klebsiella spp. were 
subjected to antimicrobial susceptibility testing by disc diffusion method with the following 
antibiotics: ampicillin, cefoxitin, ceftazidime, ceftriaxone, meropenem, amikacin, gentamicin, 
ciprofloxacin and cotrimoxazole. The results were interpreted according to the CLSI breakpoints 







Phenotypic detection of β-lactamases 
The disc approximation method that consists of ceftazidime and ceftriaxone in addition to 
amoxicillin/clavulanic acid discs was used for ESBL confirmation (14). ROSCO discs (Rosco 
Diagnostic, Taastrup, Denmark) were used for ESBL and AmpC production confirmation(15). E. 
coli ATCC 25922 and K. pneumoniae ATCC 700603 were used as negative and positive quality 
control strains, respectively. 
 
Genotypic characterization of β-lactamases 
For the DNA extraction, 18-24 hour-colonies grown on Muller Hinton agar were inoculated in 
Luria-Bertani(LB) broth (16) and incubated at 37°C with shaking. After 20 hours of incubation, 
extraction was done using Fungal/Bacterial DNA MiniPrep kit (Thermo Fisher Scientific, 
Lithuania). The PCR for detection of blaTEM, blaSHV, blaCTX,blaCMY, blaDHA, blaFOX and blaMOX 
was performed on a ThermalCycler T100TM (Bio-Rad, USA) with a final volume of 50µL (25µL 
of Master mix, 15µL of water, 4µL of each primer (Inqaba Biotechnology Industries, South Africa) 
and 2µL of the template DNA), with an initial denaturation temperature of 98oC for 10 seconds, 
extension at 72oC for 15 seconds and a final extension at 72oC for 1 minute. The annealing 
temperature for the genes was:blaTEM60
oC, blaSHV56
oC, and blaCTX57
oC. The annealing 
temperature for blaCMY was 57
oC, while that of blaDHA, blaFOX and blaMOX was 50
oC. 
The PCR products were loaded on a 1.5 % (w/v) agarose gel. The products were visualized by UV 
transillumination (Bio-Rad ChemiDocTMMP System) after staining in 0.1 mg/mL Gel Red for 15 








TABLE 1. Primers used for amplification 
Target 
enzyme Primers  Sequence (5' to 3') Anealling temperature 
TEM-1 
TEMMF AAA  ATT  CTT  GAA  GAC  G 
60oC   (29) TEMMR TTA  CCA  ATG  CTT  AAT  CA 
SHV 
SHVMF TTA  ACT  CCC  TGT  TAG  CCA 
56oC   (29) SHVMR GAT  TTG  CTG  ATT  TCG  CCC 
CTX-1 
CTXMF GGT  TAA  AAA  ATC  ACT  GCG  TC 
57oC   (27) CTXMR TTG  GTG  ACG  ATT  TTA  GCC  GC 
CMY 
CMYMF GAT  TCC  TTG  GAC  TCT  TCA  G 
57oC   (28) CMYMR TAA  AAC  CAG  GTT  CCC  AGA  TAG  C 
FOX 
FOXMF CAC  CAC  GAG  AAT  AAC  CAT 
57oC   (28) FOXMR ATG  TGG  ACG  CCT  TGA  ACT 
DHA 
DHAMF AAC  TTT  CAC  AGG  TGT  GCT  GGG  T 
57oC   (28) DHAMR CCG  TAC  GCA  TAC  TGG  CTT  TGC 
MOX 
MOXMF GCT  GCT  CAA  GGA  GCA  CAG  GAT 
50oC   (28) MOXMR CAC  ATT  GAC  ATA  GGT  GTG  GTG  C 
 
 
Genomic DNA isolation 
Genomic DNA was isolated from 35 E. coli and 21Klebsiella spp. isolates and purified using the 
Gene Jet Genomic DNA purification Kit (Thermo Scientific). Antibiotic sensitive E. coli ATCC 
25922 and β-lactam-resistant K. pneumoniae ATCC 700603 were used as controls for comparison. 
 
ERIC-PCR analysis  
The total PCR reaction volume was 10 µL, which contained 2 µL of template DNA and 
0.1µLprimers and 5 µL of DreamTaq (Thermo Scientific). The primers ERIC 1 and ERIC 2 
(Versalovic et al., 1991)were used. PCR conditions were as follows: 94°C for 3 min, 30 cycles of 
30 s of denaturation at 94°C, 1 min of annealing at 50°C, 8 min of extension at 65°C and a final 
elongation at 16 min at 65°C, in an Applied Biosystems 2720 thermal cycler. The ERIC-PCR 
products were loaded onto 1% (w/v) agarose gels and subjected to electrophoresis at 80V using 
1× TAE buffer. Amplification products were visualized by UV transillumination (Syngene, UK) 
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after staining in 0.1 mg/mL ethidium bromide for 15 min. Genotypic variation were analyzed using 
the GelCompareII version 6.0 software package (Applied Maths) by Jacquard and Unweighted 





Among 275 collected samples, 159 (57.8%) were collected from male students and 116 (42.2%) 
from females, all varying from 19 to 32 years old. The students live in separated blocks and/or 
floors for male and female students. Each floor has one kitchen where students can prepare their 
own food. There are students from different courses: Engineering, medicine, political science, 
biology, sociology, and others. As we had to go room by room explaining the student about the 
research, there were not too much difficulties in giving sample. The challenge was in convincing 
the students that the samples were only for the objectives stated in the  research.  The issue was in 
health sciences students who demonstrated difficulties to give samples, but helped us in recruiting 
the other students to participate. the student that. All students who signed the informed consent, 
gave the sample. 
 
Frequency of E. coli and Klebsiella spp. ESBL colonization 
From a total of 275 samples collected, 140 bacterial colonies grew on the MacConkey+ceftriaxone 
agar (1mg/L). Among them, 25% (35/140) were confirmed as E. coli and 15% (21/140) as 
Klebsiella spp. Among the participants in this study, 50% of the carries (28/56) were male and 
50% female, and the frequency of colonization in both sex were similar for E. coli and Klebsiella 




ESBL confirmation by double disc synergy and by ROSCO discs 
All the 56 isolates identified as E. coli (n=35) and Klebsiella spp. (n=21) were confirmed as ESBL 
producers. Among the ESBL-positive isolates, 39.3% (22/56) were cefoxitin resistant and 
confirmed with the ROSCO discs containing cefotaxime, cefotaxime+boronic acid, ceftazidime 
and ceftazidime+boronic acid as AmpC producers. 
 
Carbapenemase confirmation by Carba NP-test 
Only two isolates showed reduced susceptibility to imipenem and meropenem by disc diffusion. 
These were confirmed as carbapenemase negative by the Carba NP-test, which means that among 
the strains enrolled in this study there were no carbapenemase producers. 
 
ESBL gene identification by PCR 
The PCR results are summarized in Table 2. 
Table 2: Distribution of the ESBL enzymes according to the species 
ESBL Enzymes E. coli Klebsiella spp. Total 
TEM 10(17.9%) 2(3.6%) 12 
CTXM1 32(57%) 9(16.1%) 41 
SHV 32(57%) 7(5.4%) 39 
CMY 9(16.1%) 3(5.4%) 12 
FOX 13(23%) 4(7.1%) 17 
MOX 7(12.5%) 4(7.1%) 11 
DHA 17(30.4%) 4(7.1%) 21 
TOTAL 120 33 153 
 
Among the ESBL-positive isolates, 61% were positive for at least two enzymes, 43% were positive 
for at least three, and 25% positive for at least 4 enzymes. On the other hand, 50% (28/56) of the 
isolates contained only class A ESBL, 5.4% (3/56) only class C ESBLs, and 44.6% (25/56) both 





The E. coli and Klebsiella spp. strains showed high resistance rates to ampicilin (100% 
respectively), followed by tetracycline and co-trimoxazol (69.6%), ceftazidime (62.5%), 
ciprofloxacin (33.9%), and cefoxitin (34.8%). None of the isolates showed resistance to 
meropenem. 
Table 3: Antimicrobial resistance of ESBL-producing E. coli and Klebsiella spp. 
  Isolates 
Drugs E. coli Klebsiella spp. 
Cefoxitin 37% 47% 
Ciprofloxacin 37.1% 28.6% 
Ceftazidime 71.4% 42.9% 
Ampicillin 100% 100% 
Gentamicin 14.3% 42.9% 
Tetracycline 65.7% 76.2% 
Ceftriaxone 100% 100% 
Cotrimoxazole 62.9% 76.2% 
Imipenem 0% 0% 
 
The percentage of multi-resistance, defined as resistance to three or more antibiotics, was high 
among the isolates, with 25% (14/56) showing resistance to six antibiotics, 46% (26/56) to five 
and 19.6% to three antibiotics. In total, 78.6 % of ESBL strains were defined as multi-resistant. 
 
Antibiotic consumption and hospitalization 
No participants declared a story of  hospitalization within six months prior to the study and 87.5% 
of them had not consumed any antibiotics for at least three months. 
 
 
ERIC-PCR results for E. coli 
Distinct ERIC-PCR profiles were obtained for the 35 E. coli isolates from university students 
residing in the same residencies (Fig. 1), compared to the antibiotic susceptible E. coli ATCC 
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25922 strain.  The absence or presence of a band was noted in determining variation among the 
strains and banding patterns comprised between 2 and 14 individual bands.  Polymorphisms based 
on fragment length were obtained as a means of differentiating E. coli isolates.  Fragments of 
different molecular weights were observed in the ERIC-PCR fingerprints, ranging from 0.5 – 20 
kb (Fig.1). Amplification of different intensities was observed and visual analysis of the ERIC 
profiles included primary, secondary and tertiary amplification (Fig. 1). Primary amplification 
products refer to those products of high intensity, which appear extremely bright on the gels. 
Secondary amplification products are those products that are not as bright as the primary 
amplification products but more intense that the tertiary amplification products, while the tertiary 
amplification products are the minor amplification products of low intensity.  All isolates were 
typeable using this fingerprinting technique and band profiles were reproducibly obtained under 
similar experimental conditions on repeat amplification.  
 
The ERIC–PCR profiles allowed the differentiation of the 35 E. coli isolates into 24 ERIC-PCR 
types which were grouped into 15 clusters (A – O), with each of the clusters being sub-divided into 
multiple sub-clusters (Fig. 1). Isolates demonstrated up to 35% similarity to E. coli ATCC 25922.  
CTX-M and SHV genes were amplified from isolates in different clusters and were the most 
prevalent of the β-lactamase genes identified.  Isolates with similar profiles demonstrated varying 




ERIC-PCR results for Klebsiella spp. 
Twenty-three Klebsiella spp. isolates were selected for ERIC-PCR analysis in comparison to SHV-
containing K. pneumoniae ATCC 700603. Distinct profiles were obtained for all isolates tested 
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using ERIC-PCR fingerprinting (Fig. 2). The absence or presence of a band was noted in 
determining variation among the strains and banding patterns comprised between 2 and 16 
individual bands. Polymorphisms based on fragment length were also used as a means of 
differentiating Klebsiella spp. isolates. Fragments of different molecular weights were observed 
in the ERIC-PCR fingerprints, ranging from 0.5 – 20 kb (Fig. 2). Amplification of different 
intensities was observed and visual analysis of the ERIC profiles included primary, secondary and 
tertiary amplification. Primary amplification products refer to those products of high intensity, 
which appear extremely bright on the gels. Secondary amplification products are those products 
that are not as bright as the primary amplification products but more intense than the tertiary 
amplification products, while the tertiary amplification products are the minor amplification 
products of low intensity. All isolates were typeable using this fingerprinting technique, and band 
profiles were reproducibly obtained under similar experimental conditions on repeat amplification.   
 
The ERIC–PCR profiles allowed the differentiation of the 23 isolates into 17 ERIC-PCR types 
which were grouped into 12 clusters (A – L), with each of the clusters being sub-divided into 
multiple sub-clusters (Fig. 2). Isolates demonstrated up to 34% similarity to K. pneumoniae ATCC 
700603. CTX-M and SHV genes were the most prevalent of the β-lactamase genes amplified and 
were identified in isolates from different clusters, predominantly clusters B-G.  Isolates with 









Antibiotic resistant microorganisms are an emerging cause of infection in Mozambique and 
worldwide, but information regarding the resistance mechanisms of extended-spectrum ß-
lactamase (ESBL)-producing Enterobacteriaceae in our country remains scarce. To our 
knowledge, there are no previous studies regarding gastrointestinal ESBL colonization that 
describes the frequency of carriage among students. 
 
We have systematically collected samples from healthy students to determine the level of 
colonization by E. coli and Klebsiella spp. ESBL producer and their antibiotic susceptibility. In a 
total of 140 ceftriaxone resistant isolates from faecal samples, 25% were identified as E. coli and 
Klebsiella spp. ESBL producers. Similar results were found in a study conducted in children 
attending pre-school childcare facilities in the Lao People’s Democratic Republic where the 
prevalence was 23% (17) and in a study conducted in Korea which found 28.2%, reporting the 
frequency of E. coli to be higher (78%) than the frequency of Klebsiella spp. (18%) (18).  
 
A study recently conducted in Madagascar (12) demonstrated lower rates of colonization by ESBL 
Gram-negative bacilli compared to this study despite the fact that more species were included 
whereas our study worked only with E. coli and Klebsiella spp. 
Colonization in the intestinal gut by ESBL-producing isolates has been associated with a high risk 
for developing infection due to ESBL producers (19). To screen for carriage is the key to predict 
the risk of ESBL infection by extra intestinal pathogenic E. coli (19). An example of community 
acquired ESBL infection is E. coli community associated strains that can reach high levels of 




This study showed a high percentage of ESBL carriage compared to a study conducted in France 
where the frequency of ESBL carriage was 5.3% (21). This big difference may be because in 
developing countries, antibiotic consumption is poorly controlled and hygiene conditions are 
suboptimal (22). In Mozambique, antibiotic therapy is mostly empirical because of scarce 
microbiology facilities (30).  
 
A study conducted in United Kingdom (23)  demonstrated 31% resistance to cephalosporins, 20% 
to cotrimoxazole and 79% to tetracycline , while this study revealed higher resistance rates to 
cephalosporins and cotrimoxazole (81.3% and 69.6% respectively), but lower resistance rates to 
tetracycline.  
 
We have found 39.9% of co-existence of ESBL and AmpC β-lactamases. Our rate of ESBL/AmpC 
co-existence in Enterobacteriaceae is higher compared to the one clinically reported in Turkey as 
13.9% (36) and as 19.5% in Europe (35). 
 
Most of the isolates on this study carried blaCTX-M-15 (71.4%), followed by blaCTX-M-55 (14.3%), 
blaCTX-M-186 (9.5%) and blaCTX-M-3 (4.8%). These results are different from the findings in a study 
conducted in Kenya (28) which demonstrated 29% of the isolates carrying blaCTX-M-15, 4% carrying 
blaCTX-M-3 and no isolates carryingblaCTX-M-55 or blaCTX-M-186. However, our results are similar to 
the ones in a study conducted in Niger (21) and in Tanzania (33) that found blaCTX-M-15gene in 90% 
and 94.7% of the carriers, respectively. 
 
The blaCTX-M-15 seem to be the major type in humans (34) and exhibits enhanced catalytic 
efficiencies against ceftazidime (25). This fact can justify the reason why we have found high 
resistance rates to this antibiotic (59.5%), because in our study the blaCTX-M-15 was the most 
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predominant among the CTX-Ms. The CTX-M is most prevalent in E. coli, Klebsiella spp. and 
Proteus (26), but is mainly produced by E. coli and has become predominant in the community 
(27). 
 
In this study, we have found that no participants had a story of hospitalization within six months 
prior to the study and 87.5% of them had not consumed any antibiotics for at least three months. 
This suggests that the high antibiotic resistance rates found in this study are not related to antibiotic 
consumption or hospitalization, suggesting that the E. coli and Klebsiella spp. ESBL producers 
isolated in this study are probably community acquired. 
 
In the university residencies, there is a mix of students from different courses including medicine 
course and health sciences. These ESBL-colonized students are going to work in health 
institutions, which may constitute a reservoir of multi-resistant microorganisms that can spread 
among patients thus increasing the problem of antibiotic resistance.  
 
To control the rapid spread of ESBL among students and, consequently, among the general 
population, it is necessary to educate the students about the importance of personal and general 
hygiene and develop more studies in order to know the prevalence of colonization in different 
groups of the population. The prevalence in general may vary depending on socioeconomic status 
of individuals involved (29), which makes it difficult to estimate the prevalence in the general 
population as a whole. However, one may suppose that the prevalence in the students is high 
because of the condition they live under (eg.: many individuals sharing the same bath room and 




The multiple different strains illustrated in the REP-PCR indicates that there is at present no 
outbreak at the strain level, although there could be dissemination of one or more plasmids. One 
may speculate that students are exposed to ESBL strains from some external source like 
dissemination in the food supply. The students eat food prepared at the general kitchen at the 
student residence, but there are other alternative kitchens in each residency block to allow the 
students to cook their own food. 
Very limited is known about dissemination of  ESBL strains in the food supply in Mozambique, 
but it is known from other countries that ESBL E. coli and Klebsiella spp. may disseminate among 
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la spp. + + - - - + + S R I R S R R R S 
9 E. coli + + - - - - - S I R R S R R R S 
12 E. coli + + - - - - - S S R R S R R R S 
22 E. coli + + - + - + + R R I R S R R R S 
30 E. coli + + + - - - - I R R R S S R I S 
33 E. coli - + - - - - - S S S R R S R S S 
34 E. coli + + - - - - - S S I R R R R R S 
36 E. coli - - + - - - - S R R R S R R R S 
42 E. coli + + - - - - + S S R R S S R S S 
43 E. coli - + - - - - - S S R R S R R R S 
44 E. coli + + - - - + + R S R R S R R R S 
46 E. coli + + - + + + + R R R R R R R R S 
49 E. coli - - - + - - - R R R R S S R R S 
59 
Klebsiel
la spp. + + - - - - - R S R R S I R S S 
60 E. coli + + - - - - + S S R R S R R S S 
62 E. coli + + + - - - + R S R R S S R S S 
65 
Klebsiel
la spp. + + + - - - - S S S R R R R R S 
66 E. coli - - - - - - - S S R R S R R R S 
67 E. coli - + + + + + + R R R R S I R S S 
68 
Klebsiel
la spp. - - - - - - + S S S R S R S R S 
79 E. coli + + - - - - + S S R R S R R R S 
80 
Klebsiel
la spp. + + - + + + - R R R R S R R R S 
90 
Klebsiel
la spp. - - - - - - + S R I R S R R R S 
92 
Klebsiel
la spp. + - - - - + + R S S R R R R R S 
95 E. coli + + - - - - - S S S R S R R R S 
99 E. coli + + - - - - - S S R R S R R R S 
104 E. coli + + + - - - - I R R R S S R I S 
104/2 
Klebsiel
la spp. + + - + - - + R S R R S I R S S 
110 E. coli - + - - + + + R S S R S R S S S 
112 E. coli + - - - - - - S S S R S R S R S 
120 E. coli + - - - - - - S I R R S S R I S 
138 E. coli + + - + + + + R R R R S R R R S 
142 
Klebsiel
la spp. + + - - + + + R R R R R R R R S 
145 E. coli + + + - - - - I R R R S S R I S 
146 
Klebsiel
la spp. - + - + + + + R S I R S R I S S 
150 
Klebsiel
la spp. - + - - - - - S S I R S S R R S 
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152 E. coli + - - - - - - S S S I S S S S S 
161 
Klebsiel
la spp. + + + + + + + R R R R R R R R S 
162 E. coli + + - - - - - S S I R S S R R S 
165 
Klebsiel
la spp. + - - - - - - S I R R R R R R S 
167 
Klebsiel
la spp. + - - - - - - R I R R S S R I S 
169 E. coli + + - - - - - S S R R S R R R S 
171 
Klebsiel
la spp. + + + - - - - S S S R R R R R S 
176 
Klebsiel
la spp. - - - - - - - S S S R S R S R S 
186 
Klebsiel
la spp. + - - - - - - R I R R S S R I S 
195 
Klebsiel
la spp. + - - - + + + R I R R R R R R S 
207 E. coli + + + + - + + R I R R S R R R S 
209 E. coli + + + - + + + R R R R R R R R S 
214 E. coli + + - + + + + R R R R R R R R S 
217 E. coli + - - - + + + R S R R S R R S S 
220 
Klebsiel
la spp. + + - - - - - S I R R R R R R S 
223 E. coli + + + - - - - S R S R S R R R S 
226 
Klebsiel
la spp. + + - - - - - S S S R R R R R S 
228 E. coli + + - - - - + R R R R S R R R S 
277 E. coli + + - - - - - S S S I S S S S S 
317 
Klebsiel









Figure 1:Dendrogram representing the genetic relatedness and cluster analysis of 35E. coli, 
isolated from stool samples of University residence students, based on ERIC-PCR fingerprinting 
patterns using Jacquard index and UPGMA algorithm. The scale at the top represents percentage 
















80             
30 
152               E. coli       +      -                -                  -                  -                   -              -        
223               E. coli       +     +                 +                 -                   -                  -               -        
95                 E. coli       +     +                  -                  -                  -                  -               -        
110               E. coli       -     +                  -                  -                  +                 +             +        
214              E. coli       +     +                  -                  +                  +                +              +        
104       E. coli       +     +                  +                  -                   -                 -              -        
217              E. coli       +     -                   -                  -                   +                 +             +        
36                E. coli       -     -                   +                 -                   -                  -              -        
228              E. coli       +     +                  -                  -                   -                  -              +       
66                E. coli       -     -                  -                   -                   -                  -               -        
207              E. coli      +     +                  -                  +                  -                  +              +        
43                E. coli      -     +                  -                  -                  -                   -               -        
277              E. coli      +     +                  -                  -                  -                   -               -         
33                E. coli       -     +                  -                  -                  -                   -               -        
34                E. coli       +     +                  -                  -                  -                   -               -        
49                E. coli       -     -                  -                   +                 -                   -               -        
60                E. coli       -     -                  -                  -                  -                   -                -        
12                E. coli       +     +                  -                  -                  -                   -               -        
42                E. coli       -     -                   -                  -                  -                   -               -        
62                E. coli       +     +                  +                  -                  -                   -              +        
67                E. coli       +     +                  -                  -                  -                   -               -        
79                E. coli       +     +                  -                  -                  -                   -               +        
30                E. coli       +     +                  +                  -                  -                   -              -        
9                  E. coli       +     +                  -                  -                  -                   -               -        
99                E. coli       +     +                  -                  -                  -                   -              -        
169              E. coli       +     +                  -                  -                  -                   -              -        
120              E. coli       +     -                  -                  -                   -                   -               -        
44                E. coli       +     +                  -                  -                  -                   +              +        
22                E. coli       +     +                  -                  +                  -                  +               +        
112             E. coli       -     -                   -                  -                  -                   -                 -        
138             E. coli       +     +                   -                 +                 +                  +                +        
162             E. coli       +     +                   -                  -                  -                   -                -        
145             E. coli       +     +                   +                  -                  -                   -                -        
     Isolate code       Species  CTX-M SHV TEM            CMY MOX           FOX        DHA  
209            E. coli       +     +                   +                  -                  +                   +               +        
46               E. coli       +     +                   -                  +                  +                   +               +        
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Figure 1:Dendrogram representing the genetic relatedness and cluster analysis of 21Klebsiella spp.,isolated from stool samples of University residence 
students, based on ERIC-PCR fingerprinting patterns using Jacquard index and UPGMA algorithm. The scale at the top represents percentage similarity 





227           Klebsiella spp.      -                   -      -       -       -      -                  - 
167           Klebsiella spp.      +       -                        -       -                        -                        -                  - 
 
176           Klebsiella spp.       -                   -                  -                   -                   -                  -                  - 
  171           Klebsiella spp.      +                     +                       +                         -                         -                        -                  - 
68             Klebsiella spp.       -                     -                        -                         -                         -                        -                   -    
90             Klebsiella spp.       -                     -                        -                         -                         -                        -                   - 
146           Klebsiella spp.       -                     +                       -                         +                        +                       +                  + 
 195           Klebsiella spp       .+                    -                       -                          -                        -                         -                  - 
2               Klebsiella spp.       +                    +                       -                          -                        -                         +                + 
35             Klebsiella spp.       -                     -                        -                          -                        -                         -                 -         
59             Klebsiella spp.       +                    +                       -                          -                        -                        -                  - 
65             Klebsiella spp.       +                    +                       +                          -                        -                        -                 - 
 317           Klebsiella spp.       +                    +                       -                          -                        -                        -                  - 
 104/2        Klebsiella spp.       +                    +                       -                          +                        -                        -                  + 
 142           Klebsiella spp.       +                    +                       -                          -                        +                        +                 + 
 150           Klebsiella spp        .-                     +                      -                         -                         -                        -                  -    
 92             Klebsiella spp.      +                     -                        -                         -                         -                        +                 + 
 165           Klebsiella spp.       +                     -                        -                         -                         -                        -                 -    
 226           Klebsiella spp.      +                     +                        -                         -                         -                        -                 -    
 220           Klebsiella spp.      +                     +                        -                         -                         -                        -                  -    
 161           Klebsiella spp.       +                   +                        +                          +                       +                        +                 + 
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CHAPTER 3. CONCLUSION 
3.1. Introduction 
We have collected 275 stool samples from students living at Eduardo 
Mondlane University residencies, Maputo-Mozambique. The sample collection 
was made during six weeks between February and March 2016. The demographic 
data regarding antibiotic consumption, previous hospitalization, age and gender 
were collected with a small questionnaire. The samples were tested for presence 
of ESBL producer E. coli and Klebsiella spp. 
 
3.2. Conclusion 
 This study demonstrated that the prevalence of colonization by ESBL E. 
coli and Klebsiella spp. strains among male and female students is high. 
 The prevalence of multi-resistance among ESBL-positive E. coli and 
Klebsiella spp. is demonstrated to be high. 
 The strains demonstrated low genetic similarity among them, what means 
that they are not related. 
 Were identified different ESBL genes with different strains containing 
both class A and C β-lactamase genes. 
 
3.3.  Limitations 
The main limitations on this study was that the strain typing was not done in all 
ESBL isolates and it was not possible to determine Minimum Inhibitory 





Further studies should be carried out to monitor the ESBL carriage among the 
students living at the University residencies and identify the source of the ESBL. 
Similar studies should be done in other groups of population to explore the 
colonization in different groups. Complete sequencing of the strains should be 
done in all strains. 
 
3.5. Significance 
Our results bring new data about the carriage rate among University students in 
Maputo-Mozambique. This will help to understand the situation of colonization 
in this group of the population and to design strategies for monitoring this 
situation.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
